Form 4: DENTSPLY SIRONA Director Brian Gladden Receives Significant RSU Grant

DENTSPLY SIRONA Inc. Director Brian T. Gladden was granted 13,880 Restricted Stock Units (RSUs) on May 22, 2025, increasing his direct beneficial ownership to 28,218.209 shares.

Summary

• Brian T. Gladden, a Director of DENTSPLY SIRONA Inc. (XRAY), acquired 13,880 shares of common stock.
• The acquisition occurred on May 22, 2025, and was a grant of Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs are scheduled to vest in full one year from the grant date.
• Following this transaction, Mr. Gladden's direct beneficial ownership in DENTSPLY SIRONA Inc. increased to 28,218.209 shares.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive sign of continued alignment between the board and shareholder interests, and a standard component of compensation, indicating stability rather than a significant new development.

Positives

• The grant of Restricted Stock Units (RSUs) to a director increases alignment of their interests with long-term shareholder value.
• Equity-based compensation like RSUs is a standard practice for retaining and incentivizing key personnel and board members.

Future Outlook

The 13,880 Restricted Stock Units granted to Director Brian T. Gladden are scheduled to vest in full one year from the grant date of May 22, 2025.

Industry Context

This transaction is a routine insider equity grant, common across industries for director compensation and retention, and does not inherently reflect broader industry trends within the dental equipment and supplies sector.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard practice in corporate governance and executive compensation across various industries, including the dental equipment and supplies sector where DENTSPLY SIRONA operates.
• Companies like Align Technology (ALGN) or Henry Schein (HSIC) also commonly utilize equity-based compensation for their directors and executives to align interests with shareholders.
• The specific amount of the grant would typically be benchmarked against peer companies of similar size and market capitalization within the healthcare or medical device industry to ensure competitive compensation and retention.

Related Party Transactions

• The grant of 13,880 Restricted Stock Units to Brian T. Gladden, a Director, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance long-term shareholder value.
• Management/Board: The RSU grant serves as a form of compensation and retention for the director, incentivizing continued service and performance.

Next Steps

• Vesting of the 13,880 Restricted Stock Units on May 22, 2026.

Key Dates

Recommendation

Keywords

DENTSPLY SIRONA, XRAY, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership